4 Easy Exercises to Lower Knee Pain and Blood Sugars
Struggling with knee pain and high blood sugar levels? There are a number of exercises and tips to help manage pain and sugars. Best…
This study is for those with Type 2 Diabetes and scarring of the liver due to NASH (non-alcoholic steatohepatitis). NASH is also sometimes called “fatty liver.” Many people have a build-up of fat in the liver, and for most people, it causes no symptoms and no problems. But in some people, the fat causes inflammation and damages cells in the liver. NASH can be caused by conditions such as excess weight or other metabolic conditions when combined with certain diets and genetic backgrounds. Fatty liver is the most common cause of chronic liver disease in North America. There is currently no approved medication to help fatty liver.
Qualified participants in this study will receive a once-weekly investigational injection..
Qualified participants have a 2 out of 3 chance of receiving the study drug, or a 1 out of 3 chance of placebo. The goal of the study is to see if the study drug will help in the treatment of NASH and liver fibrosis.
To take part in the study, participants should be:
CEO and Medical Director
Director of Clinical Research
Clinical Research Coordinator
Navigator/Study Start-up Manager
Clinical Research Coordinator
Clinical Research Coordinator